Fresh analysis reveals that individuals who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop traditional diet and exercise regimens.
Findings released in a major medical journal demonstrates that while obese people frequently drop a large proportion of their body weight while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.
"Individuals using such drugs need to be cognizant of the danger of quick rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
This pace of regain suggests a return to starting mass in about 18 months.
Analyzing Treatments
The study, which examined 37 of trials involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with older methods.
The team point out that people who lose weight through diet and exercise generally see a more gradual creep back—perhaps 100 grams monthly—after stopping.
Understanding the Fast Regain
Doctors suggest the mechanism of the drugs is key to understanding the amplified rebound.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 levels far above than the body's typical production might result in the system to produce less of its own natural GLP-1, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement results in appetite is uncontrolled, making overeating far more likely."
An Ongoing Condition?
Health authorities recommend the injections for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians contend that, given the high risk of weight regain, the treatment might need to be life-long.
This opinion is reinforced by drug manufacturers, who note that the findings "emphasize the chronic character of excess weight," similar to managing diseases like diabetes.
User Testimonies
Users who have come off the medication report a powerful return of appetite.
"I experienced a switch activating and you become extremely hungry," described a patient.
This difficulty is exacerbated if users have not developed sustainable lifestyle or habit modifications during therapy.
Widespread Interest
Recent estimates indicate that millions of people in the UK have tried these injections in the past year, with desire being substantial.
- Adoption is greater among women compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
In conclusion, clinicians stress that while the jabs are potent tools for shedding pounds, they are not a permanent cure and maintained weight loss hinges on integrated behavioural changes.
